stockrow
Saturday 7 November 2026
Export IRLA’s income statement to Excel — free account
IRulya Therapeutics Inc.
IRLA Healthcare Biotechnology
- EPS
- +81.9%
- Free cash flow
- −63.7%
- Total debt
- +28.2%
Quarter to June 2026, against a year earlier
30.72
1.41
+4.81%
Follow IRLA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 13 | 13 | 26 | +41.5% | |
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | (12) | (12) | (37) | (77) | (90) | (52) | (32) | (57) | (81) | (95) | +26.6% | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | (12) | (12) | (37) | (77) | (90) | (52) | (31) | (57) | (84) | (92) | +27.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | (740.84) | (742.13) | (388.00) | (526.00) | (606.00) | (308.00) | (168.00) | (262.00) | (336.00) | (142.31) | (9.4%) | ||||||
| Cash flow | — | (595.58) | (696.13) | (349.55) | (348.31) | (423.50) | (262.91) | (98.24) | (147.50) | (165.37) | (7.65) | (14.8%) | ||||||
| Capex | — | (4.67) | (12.62) | (0.58) | (0.36) | (1.21) | (0.38) | (0.38) | (1.19) | (1.41) | 0.00 | (13.9%) | ||||||
| Free cash flow | — | (600.24) | (708.75) | (350.13) | (348.66) | (424.71) | (263.29) | (98.61) | (148.69) | (166.77) | (7.65) | (14.8%) | ||||||
| Book value | — | (1,229.09) | (1,942.02) | 1,213.00 | 1,180.69 | 798.02 | 600.56 | 456.95 | 139.37 | (142.57) | (5.76) | (23.6%) | ||||||
| Shares, m | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | +40.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | (10) | (12) | (33) | (51) | (63) | (44) | (18) | (32) | (41) | (47) | +19.7% | |||||
| Capex | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +20.9% | ||||||
| Free cash flow | — | (10) | (12) | (33) | (51) | (63) | (44) | (18) | (32) | (42) | (47) | +19.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 6 | 71 | 97 | 121 | 97 | 91 | 68 | 37 | (20) | 115 | n/m | |||||
| Net debt | — | 0 | (72) | (100) | (133) | (106) | (90) | (62) | (26) | 0 | (116) | n/m | ||||||
| Shareholders’ equity | — | (20) | (33) | 115 | 172 | 119 | 101 | 85 | 30 | (36) | (35) | +7.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (30.36) | (30.96) | (37.50) | (48.97) | (55.75) | (43.57) | (23.09) | (40.25) | (80.75) | (76.68) | (50.4) pt | |||||
| ROIC | — | 0.00 | 0.00 | (156.78) | (126.80) | (436.07) | (299.21) | (92.26) | (972.12) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | 46.25 | 47.16 | (89.27) | (53.42) | (61.85) | (47.14) | (33.81) | (98.63) | 3,016.49 | 784.09 | +2,970.2 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 16 | 23 | 37 | 55 | 21 | 32 | 36 | 38 | — | +13.2% | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
IRulya Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| EYPT EyePoint, Inc. | $30.7M | — (loss-making) | — (loss-making) | −90.49% (below 0%: shrinking) | n/m | +0.41% (above 0%: growing) | 100.00% | (19,207.10%) | Compare |
| IRLA IRulya Therapeutics Inc. | $29.8M | — (loss-making) | — | — | n/m | −63.65% (below 0%: shrinking) | 0.00% | 0.00% | |
| LITS Lite Strategy, Inc. | $29.6M | — (loss-making) | — (loss-making) | +647.96% (above 0%: growing) | n/m | +179.28% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EDSA Edesa Biotech, Inc. | $28.8M | — (loss-making) | — (loss-making) | −99.88% (below 0%: shrinking) | n/m | −81.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ANVS Annovis Bio, Inc. | $28.6M | — (loss-making) | — | — | n/m | −329.18% (below 0%: shrinking) | — | 0.00% | Compare |
| BCTX BRIACELL THERAP | $28.6M | — (loss-making) | — | — | n/m | +26.73% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ALGS Aligos Therapeutics, Inc. | $28.2M | — (loss-making) | — (loss-making) | +287.18% (above 0%: growing) | n/m | +105.91% (above 0%: growing) | 100.00% | (762.98%) | Compare |
| MGX Metagenomi Therapeutics, Inc. | $27.6M | — (loss-making) | — (loss-making) | −103.02% (below 0%: shrinking) | n/m | +7.98% (above 0%: growing) | 100.00% | 11,195.72% | Compare |
| PLRZ Polyrizon Ltd. | $27.5M | — | — | — | — | −744.51% (below 0%: shrinking) | — | — | Compare |
| Median of peers | $28.6M | — | — | −90.49% | — | +4.20% | 50.00% | 0.00% |
Pay and ownership Proxy statement filed 25 August 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 2.41m | 3.94m | 525.57 |
| 2024 | 2.73m | 3.37m | 293.38 |
| 2023 | 1.33m | 2.49m | 164.73 |
Ownership
Directors and executive officers, together
5.60%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement